Meeting
2023 ASCO Annual Meeting
Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.
Authors
Bradley Corr
University of Colorado Cancer Center, Aurora, CO
Bradley Corr , Lisa N. Abaid , James R. Mason , Ramez Nassef Eskander , Fabio Cappuccini , Katrina L. Lopez , Hans S. Keirstead , Gabriel I. Nistor , Robert O. Dillman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02033616
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5560)
DOI
10.1200/JCO.2023.41.16_suppl.5560
Abstract #
5560
Poster Bd #
255
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
First Author: Robert O. Dillman
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2023 ASCO Annual Meeting
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).
First Author: Yi Jiang
Poster
2022 ASCO Annual Meeting
Frontline therapy of anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib in patients with newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study.
First Author: Yi Jiang